This is a critical observation as clinical studies evaluating EFdA for the treatment and prevention of HIV infection were recently placed on hold by the FDA based on a decrease in total lymphocyte and CD4+ T cell counts in some participants (78). Here, CD4 is linked to HIV infectious disease.